Project Grant HT94252410682

The project "ENGINEERING NATURAL KILLER CELLS TO TARGET ACUTE MYELOID LEUKEMIA WITH HLA-DR LOSS" is being funded by a $429,000 Project Grant from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) awarded to Western University of Health Sciences in California. The goal of this 3-year research project is to develop a novel chimeric antigen receptor (CAR) natural killer (NK) cell therapy that can specifically target acute myeloid leukemia (AML) with loss of the...

This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to Seattle Children's Hospital, doing business as Seattle Children's Research Institute, supports research to develop a novel CAR T-cell therapy for patients with hepatocellular carcinoma (liver cancer). The $470,759 award, commencing on September 1, 2025, aims to prevent CAR T-cell exhaustion and improve the antitumor activity of GPC3-CAR T-cells through the precise, on-demand control...

The U.S. National Cancer Institute (NCI) has awarded a $3,480,276 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to Seattle Children's Hospital, doing business as Seattle Children's Research Institute. The funding will support a 4-year research initiative to systematically uncover the genomic heterogeneity of pediatric and adolescent/young adult Philadelphia chromosome-positive (Ph+) and ABL-class Ph-like acute lymphoblastic leukemia (ALL). The overarching goals are to...

This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), aims to investigate new strategies for preventing immune rejection of hematopoietic stem cell grafts in transplantation. The $725,971 award, with a performance period from August 15, 2025 to May 31, 2030, will fund research at the University of California, San Diego (UCSD) to explore the use of gene editing to silence mismatched human leukocyte...

This $178,000 Project Grant awarded by the National Center for Advancing Translational Sciences (NCATS), a component of the National Institutes of Health (NIH), aims to develop a bone marrow organoid system to study RUNX1-familial platelet disorder with associated myeloid malignancy (RUNX1-FPD/MM). RUNX1-FPD/MM is a rare genetic disorder that can lead to thrombocytopenia, platelet dysfunction, and a high risk of developing myelodysplastic syndrome and leukemia. The project, awarded to The...

The National Cancer Institute (NCI) awarded a $402,600 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to the Sloan-Kettering Institute for Cancer Research to develop novel chimeric antigen receptor (CAR) T-cell therapies targeting the U5 small nuclear ribonucleoprotein (U5 snRNP) complex for the treatment of acute myeloid leukemia (AML). The primary goals of this 5-year project are to develop these CAR T-cell therapies and investigate the mechanism by which U5 snRNP is...

This $683,472 Project Grant awarded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports the development of a novel targeted therapy for acute myeloid leukemia (AML). The principal investigators at the University of Cincinnati are conducting preclinical research to evaluate a differentiation-inducing agent (HOSU-53) that targets the mitochondrial enzyme DHODH. The goal is to promote AML cell differentiation, activate the immune system, and induce ferroptosis to...

This federal Project Grant award from the National Center for Advancing Translational Sciences (NCATS), CFDA 93.350, provides $489,500 to The Children's Hospital of Philadelphia (CHOP) to conduct research on the use of the compound Repsox for prophylactic intervention in Familial Platelet Disorder with associated Myeloid Malignancy (FPDMM) due to RUNX1 haploinsufficiency. The research aims to examine the effects of Repsox on RUNX1 expression, activity, and isoform usage in FPDMM hematopoietic...

This federal Project Grant award of $676,550 from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) supports research to understand the impact of socioeconomic status (SES) and adversity on hematopoietic cell transplant (HCT) outcomes in pediatric patients with high-risk hematological malignancies. The primary goals are to: 1) quantify the association between donor and recipient SES with pediatric HCT outcomes, and 2) evaluate how donor and recipient SES...

The National Cancer Institute (NCI) awarded a $1,477,396 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to the Beckman Research Institute of the City of Hope in Duarte, CA. The grant, awarded on December 1, 2024, supports a novel approach to enhance the efficacy and durability of CD19 chimeric antigen receptor (CAR) T-cell therapy for B-cell non-Hodgkin's lymphoma (B-NHL). The project involves selecting cytomegalovirus (CMV)-specific T cells, modifying them with a...